PubMed1996
The concept of Panic Disorders has itself been developed on the strength of therapeutic effects of drug treatments and it is therefore not surprising that psychotropic medications are currently the main therapeutic tool for this condition. Their use may be indicated in two differing circumstances, as treatment for Panic Attack itself or as a long-term treatment for what is properly called Panic Disorder. The latter scenario is that which has been most actively studied and represents the more original side of the question. Treatment of acute Panic Attack involves administration of sedative anxiolytics, principally benzodiazepines (BZD). Long-term treatment aiming to prevent repeated attacks is the core strategy for treatment for Panic Disorder. For the past fifteen years, a large number of research projects have shown the elective anti-panic efficacy of a number of drugs, principally antidepressants and anxiolytics. The response profile to anti-depressant treatment is characterized by a lag time which is sometimes longer than that observed when they are used solely as antidepressants; frequently they are also less well tolerated which necessitates a very gradual step-up in dosage. The "classic" MAOI (non-selective and irreversible) have a proven anti-panic effect. Selective serotonin reuptake inhibitor (SSRI) anti-depressants are currently drugs of choice in the treatment of Panic Disorder. Although the anti-panic effect appears to be common to all the various SSRI drugs available, and directly attributable to their mechanism of action, not all of them however have undergone controlled studies. In France, paroxetine is the first anti-depressant in this group to obtain a marketing authorization for this particular indication. The advantages of the SSRI drugs are principally related to their limited adverse effects and lack of toxicity, thereby making them particularly straightforward to use. Benzodiazepines (BZD) are the second group of psychotropic medications which have been shown to be effective in the treatment of Panic Disorder. The major disadvantage of the BZD for this indication is chiefly related to the major risk of promoting a dependency state with the corresponding appearance of a withdrawal syndrome when treatment is stopped. This risk constitutes a major stumbling block to the use of BZD as a first-line treatment for Panic Disorder. Various other drugs have been evaluated in the treatment of Panic Disorder with varying success. The current anti-panic pharmacopoeia therefore appears to be relatively well stocked. In this context, antidepressants-especially the SSRI drugs-are the first-line treatment of choice for Panic Disorders. In all cases, it appears useful to integrate pharmacological treatment within an overall management plan for the patient with Panic Disorder, especially if it is hoped to maintain therapeutic benefit long-term.